 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Drug:
|
F15063
|
|
Mode of action:
|
D2-D3 antagonist, D4 5HT1A agonist
|
|
Phase:
|
Discontinued
|
|
Company:
|
Fabre
|
Assié MB, Bardin L, Auclair A, Consul-Denjean N, Sautel F,
Depoortère R, Newman-Tancredi A. F15063, a potential
antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A)
agonist and D(4) partial agonist properties: (IV) duration
of brain D2-like receptor occupancy and antipsychotic-like
activity versus plasma concentration in mice. Naunyn
Schmiedebergs Arch Pharmacol . 2007 Jun ; 375(4):241-50. Abstract
Zink M, Knopf U, Mase E, Kuwilsky A, Deuschle M. Duloxetine
treatment of major depressive episodes in the course of
psychotic disorders. Pharmacopsychiatry. 2006 May 1 ;
39(3):109-11. Abstract
Assié MB, Mnie-Filali O, Ravailhe V, Benas C, Marien M,
Bétry C, Zimmer L, Haddjeri N, Newman-Tancredi A. F15063, a
potential antipsychotic with dopamine D2/D3 receptor
antagonist, 5-HT1A receptor agonist and dopamine D4 receptor
partial agonist properties: influence on neuronal firing and
neurotransmitter release. Eur J Pharmacol. 2009 Apr
1;607(1-3):74-83. Abstract
|
|
|
|
|
Text Size 
See our most recent Schizophrenia Bulletin theme Webinar: